AMD vs AstraZeneca: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AMD and AstraZeneca side by side

1. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

2. 1969AMD

   Advanced Micro Devices Founded

   Jerry Sanders and seven colleagues from Fairchild Semiconductor founded AMD on May 1, 1969, and broke ground that year on the 915 DeGuigne building in Sunnyvale, California, which remained the headquarters for more than 47 years.

3. 1975AMD

   Entry Into Microprocessors

   AMD entered the microprocessor market in 1975, moving beyond the logic devices it started with. The decision put it into direct competition with Intel and made x86 compatibility the center of its business for the next four decades.

4. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

5. 1999AMD

   Athlon Breakthrough

   Athlon launched in 1999 and matched or beat Intel on desktop performance. In March 2000 AMD announced the first 1 GHz x86 processor, days ahead of Intel, which changed how enthusiasts and PC makers judged the company.

6. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

7. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

8. 2005AMD

   Antitrust Lawsuit Against Intel

   AMD sued Intel in 2005, alleging rebates and exclusionary practices that limited its access to PC makers.

9. 2006AMD

   ATI Technologies Acquired

   AMD acquired ATI Technologies in 2006 for about $5.4B to add graphics and chipsets. The debt-funded deal strained the balance sheet just as Intel shipped Core 2, but ATI became the basis for Radeon graphics, console APUs, and later Instinct accelerators.

10. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

11. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

12. 2009AMD

    Fabless Pivot Through GlobalFoundries

    AMD moved its manufacturing operations into GlobalFoundries in 2009 and stopped owning fabs. The change removed billions of annual capital spending and let AMD buy leading-edge capacity, but it also tied the product roadmap to outside foundries.

13. 2011AMD

    Bulldozer Architecture Failure

    Bulldozer traded single-thread performance for core count at a time when most software depended on per-core speed. Reviews were poor, PC maker confidence fell, and server share collapsed, which is what forced the clean-sheet Zen project.

14. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

15. 2014AMD

    Lisa Su Becomes CEO

    AMD's board appointed Lisa Su president and CEO on October 8, 2014, succeeding Rory Read. She narrowed the company around high-performance computing and put the engineering budget behind the Zen CPU core rather than spreading it across incremental projects.

16. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

17. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

18. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

19. 2017AMD

    Ryzen, EPYC, and Chiplets Rebuild AMD

    Zen reached the market in 2017 as Ryzen for desktops and EPYC for servers. Chiplet packaging over Infinity Fabric let AMD build high core-count parts from smaller dies, improving usable yield and giving it a cost structure Intel's monolithic designs could not…

20. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

21. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

22. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

23. 2022AMD

    Xilinx Acquisition

    AMD completed the Xilinx acquisition in February 2022. The all-stock deal was announced in October 2020 at about $35B and was worth roughly $49B at close.

24. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

25. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

26. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

27. 2025AMD

    ZT Systems Acquired and Its Factories Sold

    AMD closed the ZT Systems purchase on March 31, 2025, paying $3.2B in cash plus 8.3 million shares for rack-scale AI systems design.

28. 2025AMD

    OpenAI Agrees to Deploy 6 Gigawatts of AMD GPUs

    On October 6, 2025 AMD and OpenAI announced a multi-year agreement covering 6 gigawatts of AMD GPUs, starting with a 1 gigawatt Instinct MI450 deployment in the second half of 2026.

29. 2025AMD

    Record $34.6B Revenue

    AMD reported FY2025 revenue of $34.6B, up 34%, with net income of $4.3B and a 50% gross margin.

30. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

31. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

32. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

33. 2026AMD

    Meta Agrees to Deploy Up to 6 Gigawatts of AMD GPUs

    On February 24, 2026 AMD and Meta announced a multi-year agreement for up to 6 gigawatts of Instinct GPUs.

34. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

35. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

36. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

Acquisitions

Questions about AMD vs AstraZeneca